Hot Features
Premium
Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 2,657 |
|
|||||
| News | - | ||||||
| Day High | 5.6163 | Low High |
|||||
| Day Low | 5.14 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Aprea Therapeutics Inc | APRE | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.2499 | 4.88% | 5.37 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 5.14 | 5.14 | 5.6163 | 5.37 | 5.1201 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 125 | 2,657 | US$ 5.23 | US$ 13,900 | - | 2.78 - 8.8465 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 15:51:06 | 23 | US$ 5.14 | USD |
Aprea Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 20.07M | 3.74M | - | 583k | -14.29M | -3.82 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Aprea Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 2/06/2024 | 16:01 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2/04/2024 | 23:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness |
| 2/02/2024 | 15:26 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/26/2024 | 06:13 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/26/2024 | 05:03 | Edgar (US Regulatory) | Form S-3 - Registration statement under Securities Act of.. |
| 1/04/2024 | 15:16 | Edgar (US Regulatory) | Form 8-K - Current report |
| 11/09/2023 | 15:20 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee.. |
| 11/09/2023 | 15:15 | Edgar (US Regulatory) | Form 8-K - Current report |
| 11/09/2023 | 15:10 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 10/16/2023 | 16:29 | Edgar (US Regulatory) | Form 8-K - Current report |
| 10/13/2023 | 06:31 | Edgar (US Regulatory) | Form 8-K - Current report |
| 9/11/2023 | 07:30 | Edgar (US Regulatory) | Form 8-K - Current report |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical APRE Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 5.68 | 5.98 | 5.1201 | 5.37 | 5,294 | -0.31 | -5.46% |
| 1 Month | 6.04 | 6.80 | 5.1201 | 6.14 | 9,240 | -0.67 | -11.09% |
| 3 Months | 5.01 | 8.8465 | 4.9401 | 6.64 | 35,137 | 0.36 | 7.19% |
| 6 Months | 3.93 | 8.8465 | 3.35 | 6.12 | 22,028 | 1.44 | 36.64% |
| 1 Year | 3.86 | 8.8465 | 2.78 | 4.70 | 26,231 | 1.51 | 39.12% |
| 3 Years | 91.60 | 156.00 | 2.78 | 80.01 | 623,210 | -86.23 | -94.14% |
| 5 Years | 309.20 | 1,062.20 | 2.78 | 118.71 | 563,312 | -303.83 | -98.26% |
Aprea Therapeutics Description
| Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). |
